Tozorakimab

Tozorakimab
Monoclonal antibody
Type	?
Target	Interleukin 33
Clinical data
Other names	MEDI 3506
Identifiers
CAS Number	2376858-66-9;
UNII	OHZ2MEL7FD;

Tozorakimab (formerly MEDI 3506) is a monoclonal antibody against interleukin-33 (IL-33) that works via RAGE and epidermal growth factor receptors.^[1]^[2]^[3]^[4]

References

^ Wilkinson, Tom; De Soyza, Anthony; Carroll, Miles; Chalmers, James D.; Crooks, Michael G.; Griffiths, Gareth; Shankar-Hari, Manu; Ho, Ling-Pei; Horsley, Alex; Kell, Chris; Lara, Beatriz; Mishra, Biswa; Moate, Rachel; Page, Clive; Pandya, Hitesh; Raw, Jason; Reid, Fred; Saralaya, Dinesh; Scott, Ian C.; Siddiqui, Salman; Ustianowski, Andy; van Zuydam, Natalie; Woodcock, Ashley; Singh, Dave (September 2023). "A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2". ERJ Open Research. 9 (5): 00249–2023. doi:10.1183/23120541.00249-2023. PMC 10588785. PMID 37868151.
^ Cazzola, M.; Rogliani, P.; Calzetta, L.; Matera, M.G. (2023). "Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease". Drugs of the Future. 48 (2): 101. doi:10.1358/dof.2023.48.2.3474010. S2CID 256560283.
^ Scott, I C; England, E; Rees, D G; Erngren, T; Chaillan Huntington, C; Houslay, K F; Sims, D A; Hollins, C; Hinchy, E C; Colley, C; Corkill, D J; Cohen, E S (4 September 2022). "Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction". 05.01 - Airway pharmacology and treatment. p. 2467. doi:10.1183/13993003.congress-2022.2467.
^ England, Elizabeth; Rees, D. Gareth; Scott, Ian Christopher; Carmen, Sara; Chan, Denice T. Y.; Chaillan Huntington, Catherine E.; Houslay, Kirsty F.; Erngren, Teodor; Penney, Mark; Majithiya, Jayesh B.; Rapley, Laura; Sims, Dorothy A.; Hollins, Claire; Hinchy, Elizabeth C.; Strain, Martin D.; Kemp, Benjamin P.; Corkill, Dominic J.; May, Richard D.; Vousden, Katherine A.; Butler, Robin J.; Mustelin, Tomas; Vaughan, Tristan J.; Lowe, David C.; Colley, Caroline; Cohen, E. Suzanne (17 June 2023). "Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction". Scientific Reports. 13 (1): 9825. Bibcode:2023NatSR..13.9825E. doi:10.1038/s41598-023-36642-y. ISSN 2045-2322. PMC 10276851. PMID 37330528.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Wilkinson, Tom; De Soyza, Anthony; Carroll, Miles; Chalmers, James D.; Crooks, Michael G.; Griffiths, Gareth; Shankar-Hari, Manu; Ho, Ling-Pei; Horsley, Alex; Kell, Chris; Lara, Beatriz; Mishra, Biswa; Moate, Rachel; Page, Clive; Pandya, Hitesh; Raw, Jason; Reid, Fred; Saralaya, Dinesh; Scott, Ian C.; Siddiqui, Salman; Ustianowski, Andy; van Zuydam, Natalie; Woodcock, Ashley; Singh, Dave (September 2023). "A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2". ERJ Open Research. 9 (5): 00249–2023. doi:10.1183/23120541.00249-2023. PMC 10588785. PMID 37868151.

[2] Cazzola, M.; Rogliani, P.; Calzetta, L.; Matera, M.G. (2023). "Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease". Drugs of the Future. 48 (2): 101. doi:10.1358/dof.2023.48.2.3474010. S2CID 256560283.

[3] Scott, I C; England, E; Rees, D G; Erngren, T; Chaillan Huntington, C; Houslay, K F; Sims, D A; Hollins, C; Hinchy, E C; Colley, C; Corkill, D J; Cohen, E S (4 September 2022). "Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction". 05.01 - Airway pharmacology and treatment. p. 2467. doi:10.1183/13993003.congress-2022.2467.

[4] England, Elizabeth; Rees, D. Gareth; Scott, Ian Christopher; Carmen, Sara; Chan, Denice T. Y.; Chaillan Huntington, Catherine E.; Houslay, Kirsty F.; Erngren, Teodor; Penney, Mark; Majithiya, Jayesh B.; Rapley, Laura; Sims, Dorothy A.; Hollins, Claire; Hinchy, Elizabeth C.; Strain, Martin D.; Kemp, Benjamin P.; Corkill, Dominic J.; May, Richard D.; Vousden, Katherine A.; Butler, Robin J.; Mustelin, Tomas; Vaughan, Tristan J.; Lowe, David C.; Colley, Caroline; Cohen, E. Suzanne (17 June 2023). "Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction". Scientific Reports. 13 (1): 9825. Bibcode:2023NatSR..13.9825E. doi:10.1038/s41598-023-36642-y. ISSN 2045-2322. PMC 10276851. PMID 37330528.

[1]

[2]

[3]

[4]